The article is a fragment of the research work of the Department of Phthisiology and Pulmonology of the Zaporizhzhia State Medical University under the grant "Evaluation of the results of GenoTypeMTBDRplus v.2 implementation for the early diagnosis of multi-resistant forms of tuberculosis in Zaporizhzhia region, Ukraine" (2016-2017). Logistics: Merrier Foundation (France) on the basis of a memorandum between Zaporizhzhia State Medical University and Merrier Foundation (France), 2015. Multidrug resistant tuberculosis (MDRTB) is the most common infectious disease and the most unfavorable form of tuberculosis. The GenotypeMTBRplus v.2 provides rapid identification of the M. tuberculosis complex and the detection of gene mutations in rpoB (Rif) codon and mutations in the katG and inhA codons that are associated with isoniazid resistance. Study objective is to evaluate the obtained results of the study of clinical specimens of sputum using GenoTypeMTBDRplus v.2 test system for the early diagnosis of MRTB in Zaporizhzhia region. Study object and methods. 200 patients with new and repeated cases of tuberculosis with the presence of bacterial excretion provided one sputum sample each which was used for microscopy, Genexpert MTB/RIF and GenoTypeMTBDRplus v.2 tests, cultures on the Levenstein-Jensen medium with MBT cultures. The decontamination of clinical specimens was carried out in the microbiological laboratory of the III level of Municipal Establishment "Zaporizhzhia Regional Tuberculosis Clinical Dispensary" using Eppendorf ThermoStat C (Germany). Study was carried out using the GenoTypeMTBDRplus test system v.2 (Hain Lifescience GmbH, Germany) in the department of molecular genetic research of the Department of Microbiology, Virology and Immunology of the Zaporizhzhia State Medical University in accordance with the stepwise manufacturer's instructions. Study results. The diagnosis of resistance to Rif in the GenoTypeMTBDRplus, v.2 test was higher by 18% than in the Genexpert MTB/RIF test (46,5 % versus 28,5 %, p˂0,001). When using the GenoTypeMTBDRplus, v.2 test system in Zaporizhzhia region, a significantly higher mutation rate in the rpoB gene (46,5 %) and simultaneous mutations in the 2 genes of katG + inhA (34 %) are determined. In this case, simultaneous mutations in 3 genes of rpoB + katG + inhA are diagnosed in 26,5 % of cases. Irrespective of the concentration of acid-resistant bacteria in the smear, the multidrug resistance (37,5 %) is significantly more likely to be diagnosed compared with isolated resistance to isoniazid (28,7 %) or rifampicin (2,2 %) and sensitivity of the samples (31,6 %). The sensitivity of the GenoTypeMTBDRplus test system, v.2 is 97,2 %, and the specificity is 85 %. Conclusions. Thus, performance of GenoTypeMTBDRplus, v.2 tests is more complicated than Genexpert MTB/RIF, and the tests are more sensitive. In patients with new and repeated cases of tuberculosis with the presence of bacteria, the use of GenoTypeMTBDRplus, v.2 test system provides 2 days to diagnose MDRTB in 37,5 % of cases and to start the optimal treatment of antimycobacterial therapy in a timely manner for these patients.

Keywords: multidrug resistant tuberculosis, diagnosis, GenoTypeMTBDRplus

Full text: PDF (Ukr) 245K

1. Barbova AI, Zhurylo OA, Zherebko NM, Chayka AO. Poryadok vykorystannya molekulyarno-henetychnykh metodiv u laboratoriyakh z diahnostyky tuberkulozu v Ukraini: metodychni rekomendatsiyi. Kyiv, 2014. 17 s. [Ukrainian]
2. Borovyk SP. Multyrezystentnyi tuberkuloz: aktualni pytannya vedennya khvorykh, mizhnarodni pidkhody ta natsionalnyi dosvid [digital resource]. Ukrainskyi medychnyi chasopys. 2015 [tsytovano 2015 Kvit. 06]. Available from: http://www.umj.com.ua/article/85659/multirezistentnij-tuberkuloz-aktualni-pitannya-vedennya-xvorix-mizhnarodni-pidxodi-ta-nacionalnij-dosvid. [Ukrainian]
3. Zhurylo OA, Barbova AI, Cherenko SO., Popova KYe, Pavlenko OM, Chayka AO. Alhorytm diahnostyky khimiorezystentnoho tuberkulozu z kompleksnym vykorystannyam heno- ta fenotypichnykh metodiv v bakteriolohichnykh laboratoriyakh protytuberkuloznykh zakladiv Ukrainy: metodychni rekomendatsiyi. Kyiv. 2013. 21 s. [Ukrainian]
4. Ignateva O. A. Lekarstvennaya ustoychivost shtammov Mycobacterium tuberculosis i optimizatsiya diagnosticheskikh algoritmov na primere Samarskoy oblasti [dissertatsiya]. Samara: Samar gos un-t; 2015. 157 s. [Russian]
5. Nikolaevskiy VV, Balabanova YaM, Mironova SA, Kontsevaya IS, Ignateva OA, Chinkova YuD, i dr. Chuvstvitelnost i spetsifichnost molekulyarnogeneticheskoy test-sistemy Hain MTBDRplus dlya ekspress-diagnostiki lekarstvennoy chuvstvitelnosti mikobakteriy tuberkuleza na materiale mokroty. Problemy tuberkuleza i bolezney legkikh. 2010; 4: 28-34. [Russian]
6. Raznatovska OM, Mikhaylova AO, Kostenko IA. Effektivnost Genexpert MTB/RIF u bolnykh s novymi sluchayami i retsidivami tuberkuleza legkikh. Aktualnaya infektologiya. 2015; 2: 55-7. [Russian]
7. Raznatovskaya EN, Khudyakov GV, Gritsova NA. Molekulyarno-geneticheskie metody diagnostiki i ikh ispolzovanie vo ftiziatrii. Suchasni medichni tekhnologiyi. 2016; 2: 63-71. [Russian]
8. Fedorin IM, Nikolaevskiy VV, Balabanova YaM, Malamanova NA, Mironova SA, Ignateva OA, i dr. Chuvstvitelnost i spetsifichnost molekulyarno-geneticheskoy test-sistemy Hain MTBDRplus dlya ekspress- diagnostiki lekarstvennoy chuvstvitelnosti mikobakteriy tuberkuleza na materiale mokroty. Problemy tuberkuleza i bolezney legkikh. 2010; 4; 28-34. [Russian]
9. Filatova OV, Boyko MG. Rol genetichnikh doslidzhen v likuvanni tuberkulozu. Visnik problem biologiyi i meditsini. 2013; 2 (99): 221-3. [Ukrainian]
10. GenoType® MTBDRplus. Instruction for Use. Hain Lifescience. Nehren, Germany. 2009. 144 р.
11. Kipiani M, Mirtskhulava V, Tukvadze N, Magee M, Blumberg HM, Kempker RR. Significant clinical impact of a rapid molecular diagnostic test (Genotype MTBDRplus assay) to detect multidrug-resistant tuberculosis. Clin Infect Dis. 2014; 59 (11): 1559-66. https://www.ncbi.nlm.nih.gov/pubmed/25091301. https://www.ncbi.nlm.nih.gov/pmc/articles/4357804. https://doi.org/10.1093/cid/ciu631.
12. World Health Organization. Automated real-time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance: Xpert MTB/RIF assay for the diagnosis of pulmonary and extrapulmonary TB in adults and children. WHO/HTM/TB/2013.16. 2013. 79 р.
13. World Health Organization. The use of molecular line-probe assay for the detection of resistance to second-line anti-tuberculosis drugs. WHO expert group meeting report Geneva: February 2013. WHO/HTM/TB/2013.01. 2013. 52 р.